Background.
To evaluate the effectiveness of oseltamivir and amantadine for the treatment of influenza with respect to various clinical factors, a prospective multicenter study of the influenza season of 2002-2003 was done with 2163 patients whose condition was diagnosed by an antigen-detection test kit.
Methods. Oseltamivir was administered to 803 patients with influenza A (A+Os group) and 684 patients with influenza B (B+Os group). Amantadine was administered to 676 patients with influenza A (A+Am group).
Results. For each group, the duration of fever (i.e., body temperature, у37.5ЊC) was significantly shorter in patients who received the drug within 12 h after the onset of symptoms than in patients who received the drug 112 h after the onset. For all 3 groups, the duration of fever was shorter in patients with a highest temperature !39ЊC than in patients with temperatures у39ЊC. The duration of fever was significantly longer for the B+Os group than for the A+Os group. Multiple regression analysis found that the type of influenza, the highest body temperature, and the time between the onset of symptoms and the start of treatment are independent factor that influence the duration of fever.
Conclusions. Early administration increases the benefit of anti-influenza drugs-not only the benefit of oseltamivir treatment for influenza A, but also the benefit of amantadine treatment for influenza A and oseltamivir treatment for influenza B. Oseltamivir may be less effective as a treatment for influenza B than for influenza A. A highest body temperature of у39ЊC was an indicator of a longer duration of fever.
Oseltamivir, an oral neuraminidase inhibitor, has recently become a popular treatment for influenza in Japan. Clinical assessments of oseltamivir and amantadine for treatment of influenza have been reported separately [1] [2] [3] [4] [5] [6] [7] [8] [9] ; however, the influences of patient age, virus type, and vaccination status have not been fully documented. Furthermore, comparisons of the outcomes of oseltamivir treatment with the outcomes of amantadine treatment for influenza A and comparisons of the outcomes of oseltamivir treatment for influenza A with those for influenza B in a clinical setting had not been previously reported.
In recent years, commercialized rapid diagnosis kits have made it possible to diagnose influenza types A and B easily in outpatient clinics [10] [11] [12] . We assessed the clinical effectiveness of influenza vaccination in the 2001-2002 influenza season by using an Internet-based data-collection system organized by the Japan Physicians Association [13] . This system enabled us to enroll a large number of patients from throughout Japan within a short period of time.
In the present study, patients with influenza diagnosed by rapid detection kits were enrolled and observed, and the primary end point was the duration of fever. The results of treatment with oseltamivir or amantadine and the influences of age, sex, virus type, the highest body temperature, and the time from onset of symptoms to administration of treatment are discussed.
METHODS

Study procedures.
Family doctors, pediatricians, and physicians at 42 clinics who belong to the Influenza Study Group of the Japan Physicians Association participated in the study. Patients were enrolled from 6 December 2002 through 11 April 2003. As a rule, all patients in 42 clinics from throughout Japan who had influenza diagnosed by commercialized antigen detection kits and who received oseltamivir or amantadine therapy within 48 h after the onset of symptoms were registered. For patients with influenza A, the decision of whether to administer oseltamivir or amantadine was left to the discretion of the clinicians, who considered the background and characteristics of the patient, such as baseline disease and age, and the patient's preferences. Oseltamivir was the only therapy option given to patients with influenza B. No geographical or socioeconomic differences were shown for the rates of prescription of these 2 anti-influenza drugs. In principle, enrollment was done with oral consent. Follow-up data were collected by self-reported questionnaires, phone calls, or mail.
For diagnosis, commercialized antigen detection kits based on lateral-flow immunoassay (Capilia FluA,B; Nippon Becton Dickinson) were mainly used. Other kits based on enzyme immunoassay (Influ AB Quick"SEIKEN"; Denka Seiken), lateralflow and enzyme combined immunoassay (Espline Influenza A&B; Fujirebio), and immunochromatography (RapidTesta FLU AB; Daiichi Pure Chemicals) were also used to test specimens from throat swabs, nasal swabs, or nasal aspirates. Both virus isolation and serological diagnosis were done for 152 patients with influenza A to distinguish strain A/H3N2 from strain A/H1N1. Virus isolation was done by use of standard methods with MadinϪDarby canine kidney cells. A у4-fold elevation of serum titer on a hemagglutination inhibition test was considered a positive result.
Oseltamivir (75 mg for adults and for children who weighed у37.5 kg and 2 mg/kg for children who weighed !37.5 kg) was administered orally twice daily both to patients with influenza A and to patients with influenza B. Amantadine (50 mg for adults and 1.5-2.5 mg/kg for children) was administered twice daily to patients with influenza A only. Both drugs were prescribed for 5 days. For some patients, administration of drugs was discontinued if symptoms abated in !5 days.
Age, sex, vaccination status, the result of the antigen detection kit test, the drug administered, and the highest body temperature during the course of the disease were recorded for patients. An influenza-related fever was defined as a body temperature of у37.5ЊC. The time from the onset of any symptom to the administration of an anti-influenza drug was recorded by the physician (0-12 h, 13-24 h, or 25-48 h). The duration of fever after the onset of symptoms (0-12 h, 13-24 h, 25-48 h, 49-72 h, or 172 h) was reported by the patient or an attending family member. All data were collected using an Internet-based protocol in which participating physicians sent their data to a central computer system based on a Pentium workstation running a Structured Query Language (SQL) database and on a Web server located in a secure room at the Gifu City Medical Association. All participating doctors were given an identification number and a password and were able to access the computer system via the Internet to input data into the SQL database.
Statistical analysis. Student's t test was performed to compare the duration of fever between groups. A P value of р.05 was considered to be statistically significant. Multiple regression analysis was done to determine the factors affecting the duration of fever, such as age, sex, vaccination status, the highest body temperature, the influenza type, the drug administered, and the time from the onset of symptoms to the start of treatment. Numeric variants were assigned to each subgroup on the basis of the time from the onset of any symptom to the administration of an anti-influenza drug and the duration of fever.
RESULTS
Patient characteristics.
A total of 2163 patients were enrolled and were divided into 3 groups: 803 patients with influenza A treated with oseltamivir therapy (group A+Os), 676 patients with influenza A treated with amantadine therapy (group A+Am), and 684 patients with influenza B treated with oseltamivir therapy (group B+Os). The type of influenza was diagnosed by the commercial antigen detection kit Capilia FluA,B in 1790 cases, Influ AB Quick"SEIKEN" in 91 cases, Espline Influenza A&B in 167 cases, and RapidTesta FLU AB in 84 cases and by other detection methods in 31 cases. The demographic data of the patients are summarized in table 1. The mean age (‫ע‬SD) was lower in group B+Os (14.9 ‫ע‬ 14.3 years) than in groups A+Os and A+Am (29.6 ‫ע‬ 21.4 years and 22.2 ‫ע‬ 20.2 years, respectively). No significant differences between the groups were found for the mean of the highest body temperature, ratio of female-to-male patients, or vaccination status. Influenza virus isolation was done for 152 cases of influenza A. The 135 virus isolates found were all A/H3N2.
Time from onset of symptoms to start of treatment. The duration of fever for all 3 groups was significantly shorter in patients administered drugs within 12 h after the onset of symptoms than in patients administered drugs at 13-24 h or 25-48 h after onset. The duration of fever was significantly longer for patients in group B+Os than for patients in groups A+Os and A+Am. There were no significant differences between patients in groups A+Os and A+Am who were administered drugs at 0-12 h, 13-24 h, or 25-48 h after onset (see table 2 ).
Highest body temperature. The duration of fever for all 3 groups was significantly longer in patients with a highest body temperature у39ЊC than in patients with a highest body temperature !39ЊC. Among patients with a highest body temper- ature у39ЊC, the duration of fever was significantly longer for those in group B+Os than for those in groups A+Os and A+Am (see table 3 ). Patient age. The duration of fever was significantly longer for patients in groups A+Am and B+Os aged 0-6 years than for those aged 7-15 years and 16-64 years ( and P ! .001 P ! in group A+Am; and in group B+Os). The .001 P ! .01 P ! .001 duration of fever was significantly shorter for patients aged 0-6 years in group A+Os than for those in group B+Os (P ! ). No significant differences between groups in the duration .01 of fever were found for patients aged 16-64 years and у65 years (see table 4 ).
Multiple regression analysis. The factors analyzed by multiple regression analysis and the corresponding P values are listed in table 5. The type of influenza, time from onset of symptoms to administration of treatment, and highest body temperature were found to be independent factors that affect the duration of fever. Sex, age, and vaccination status were not independent factors, nor was the drug administered (oseltamivir or amantadine).
Adverse reactions. Minor adverse reactions were reported by 19 patients in group A+Os, 8 patients in group A+Am, and 1 patient in group B+Os. No severe adverse reactions were reported.
DISCUSSION
An increased benefit from the early administration of oral oseltamivir has been reported. A report by Aoki et al. [7] included 958 patients with laboratory-confirmed influenza (944 with influenza A, 6 with influenza B, and 8 with influenza types A and B); however, the number of patients with influenza B was too small to show a significant finding. Thus, an increased benefit from the early administration of oseltamivir therapy for influenza B-or amantadine therapy for influenza A-had not been well documented. In the present study, the duration of fever after the start of treatment in all 3 groups (A+Os, A+Am, and B+Os) was significantly shorter in patients who received medication within 12 h of the onset of symptoms than in patients who received medication 112 h after onset. These results suggest that early administration increases the benefits of treatment with oseltamivir for both influenza A and influenza B and of treatment with amantadine for influenza A. Because both oseltamivir and amantadine affect the replication phase of the influenza virus, early inhibition of viral replication may hasten recovery.
The duration of fever was longer for patients in group B+Os than for patients in group A+Os, for all subgroups (table 2) . These results suggest that oseltamivir therapy is less beneficial for influenza B than it is for influenza A. Studies of the in vitro antiviral activity of oseltamivir against laboratory strains of the influenza virus by use of culture and enzymatic assays [14] [15] [16] have revealed that the drug concentration required to inhibit plaque formation or a viral cytopathic effect by 50% (IC 50 ) differed by type or strain of virus. Boivin and Goyette [16] , who used a chemiluminescent neuraminidase assay, reported that the influenza B virus was less susceptible than the influenza A virus to oseltamivir and zanamivir. These in vitro results may be relevant to our results that show oseltamivir to be less effective against influenza B than against influenza A in a clinical setting.
No significant difference between the effectiveness of oseltamivir and that of amantadine was shown for influenza A. The duration of fever was significantly longer for patients in groups A+Am and B+Os aged 0-6 years than for those aged 7-15 years and 16-64 years. However, it is not clear whether age itself is an important factor or whether the dosage of antiinfluenza drug that was given to children aged !7 years may be insufficient to effectively inhibit virus replication. Further investigation should be done to investigate this issue.
The duration of fever was longer in patients with a highest NOTE. A+Os, the group of 803 patients with influenza A treated with oseltamivir therapy; A+Am, the group of 676 patients with influenza A treated with amantadine therapy; B+Os, the group of 684 patients with influenza B treated with oseltamivir therapy; NS, not significant. NOTE. A+Os, the group of 803 patients with influenza A treated with oseltamivir therapy; A+Am, the group of 676 patients with influenza A treated with amantadine therapy; B+Os, the group of 684 patients with influenza B treated with oseltamivir therapy; NS, not significant. NOTE. A+Os, the group of 803 patients with influenza A treated with oseltamivir therapy; A+Am, the group of 676 patients with influenza A treated with amantadine therapy; B+Os, the group of 684 patients with influenza B treated with oseltamivir therapy; NS, not significant. body temperature of у39ЊC than in patients with a highest body temperature !39ЊC. A higher body temperature may reflect higher viral replication. Also, an association between increased viral number and higher cytokine levels has been reported elsewhere [17, 18] . In this context, an increased dosage or a combination of anti-influenza drugs may improve clinical outcomes, such as the duration of fever in patients with a high body temperature, especially for infants and children.
Vaccination is a useful tool for the prevention of influenza infection. The ability of vaccination to mitigate the clinical symptoms of influenza has also been shown. However, the vaccination status was not found to be an independent factor influencing the effectiveness of anti-influenza drugs in the present study. One possible explanation is that anti-influenza drugs are much more effective than vaccination in reducing the duration of fever in influenza patients.
The benefits of oseltamivir for the treatment of influenza types A and B and of amantadine for the treatment of influenza A were confirmed in a clinical setting with a large number of patients. The early administration of the anti-influenza drugs increased the benefits significantly. In this context, community education focused on getting patients to visit a clinician as soon as possible after the onset of symptoms and establishing antiinfluenza drug-administration guidelines for physicians will be helpful in maximizing the benefits of these drugs. The effectiveness of amantadine therapy was comparable to that of oseltamivir therapy for adults with influenza A, in terms of reducing the duration of fever. Other aspects, such as patient satisfaction with the treatment and related absences from the workplace, should be investigated to determine possible further benefits of oseltamivir therapy. However, the information obtained from the present study may contribute to improved prescription of anti-influenza drugs by medical practitioners.
